BioOra Partners with Cincinnati Children's to Advance Next-Generation CAR-T Therapy for Pediatric Leukemia
核心洞察
BioOra and Cincinnati Children's Hospital Medical Center have formed a strategic partnership to advance Atla-cel (搜索), a third-generation CD19 (搜索)-directed CAR-T therapy, into clinical development for children with relapsed or refractory B-cell acute lymphoblastic leukemia (搜索).
Atla-cel (搜索) demonstrated markedly reduced neurotoxicity in adult trials from the ENABLE programme, positioning it as a compelling candidate for pediatric investigation where neurotoxicity carries heightened developmental risks.
The proposed global clinical programme will enroll patients across the United States, New Zealand, and potentially Australia, with Cincinnati Children's leading trial management and Dr. Stella Davies serving as principal investigator.
BioOra Limited (搜索) and Cincinnati Children's Hospital Medical Center have announced a strategic partnership to advance Atla-cel (搜索) (atlacabtagene autoleucel (搜索)) into clinical development for children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia (搜索) (B-ALL). The collaboration leverages promising adult safety data showing markedly reduced neurotoxicity, addressing a critical barrier to CAR-T therapy adoption in pediatric patients.
Addressing Critical Safety Concerns in Pediatric CAR-T
Despite significant advances in frontline therapy, children with relapsed or refractory B-ALL (搜索) face poor long-term outcomes and limited treatment options. While first-generation approved CAR-T therapies have demonstrated meaningful efficacy, cytokine release syndrome (搜索) (CRS) and immune effector cell-associated neurotoxicity syndrome (搜索) (ICANS) remain barriers to broader adoption, especially in pediatric patients where neurotoxicity carries heightened developmental risks and typically requires intensive inpatient monitoring.
Atla-cel (搜索) is a third-generation CD19 (搜索)-directed CAR-T therapy incorporating design advances intended to enhance anti-tumor activity and improve the tolerability profile compared with earlier-generation approaches. Results from the Phase 1 ENABLE-1 study in adults with relapsed or refractory lymphoma (搜索), presented at the 2024 American Society of Hematology Annual Meeting, demonstrated promising complete response rates alongside a safety profile notable for low rates of serious CRS and, critically, markedly reduced ICANS.
"In children, ICANS is not a side effect to be managed, it is an unacceptable risk," according to the partnership announcement. "The developing brain is uniquely vulnerable to immune-mediated neurotoxicity, and this has kept CAR-T therapy from reaching many of the patients who need it most."
Global Clinical Programme Structure
The proposed pediatric B-ALL clinical programme will enroll patients across the United States, New Zealand, and potentially Australia, with trial management from Cincinnati Children's. The trial will be led by Stella M. Davies, MBBS, PhD, MRCP, Institute Co-Executive Director of the Cancer and Blood Diseases Institute and Director of the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's, ranked the #1 cancer care provider in the United States by US News and World Report.
Dr. Davies is a recognized leader in pediatric hematology-oncology and hematopoietic cell transplantation and currently serves as President-Elect of the American Society for Transplantation and Cellular Therapy. As part of the collaboration, Steve Davis, MD, President and Chief Executive Officer of Cincinnati Children's, joins the BioOra Board of Directors.
Leadership Perspectives on Therapeutic Potential
"Children with relapsed B-ALL deserve effective, safer, and more accessible therapies," said Laurence Cooper, MD, PhD, pediatric oncologist and Board Member of BioOra. "The ENABLE programme has given us confidence in Atla-cel (搜索)'s adult safety profile; markedly reduced neurotoxicity is not a minor footnote in pediatric oncology, it is central to whether a therapy can safely be used in children."
Stella M. Davies emphasized the clinical significance: "Relapsed B-ALL remains one of the toughest problems in childhood cancer. The low neurotoxicity signals from the ENABLE programme make Atla-cel (搜索) a compelling candidate for pediatric investigation, and if that profile holds in children, it could mean bringing life changing CAR-T therapy to more kids."
The markedly low ICANS rates observed in adult studies provide the strongest rationale yet for pediatric evaluation and raise the prospect of outpatient delivery that would free children and families from the prolonged inpatient stays that currently approved therapies require.
Manufacturing and Development Infrastructure
BioOra is a commercial-stage cell therapy company headquartered in Wellington, New Zealand, focused on developing and commercializing next-generation cell therapies for cancer patients. Atla-cel (搜索) is currently in a Phase 2 ENABLE-2 registration trial for adults with relapsed or refractory B-cell lymphoma (搜索). BioOra's Health & Technology Centre in Christchurch is a purpose-built GMP manufacturing facility designed to operate the Cocoon® platform at scale to support regional and international demand.
"This collaboration reflects our conviction that next-generation CAR-T design, disciplined clinical execution, and automated manufacturing can together transform outcomes for children with ALL," said John Robson, Chief Executive Officer of BioOra. "Cincinnati Children's brings the scientific depth, pediatric expertise, and global credibility this programme demands."
The partnership with Cincinnati Children's, one of the world's leading pediatric academic medical centers with deep expertise in hematology, oncology, and cellular therapies, leverages clinical data from the ENABLE trial programme, conducted in collaboration between BioOra and the Malaghan Institute of Medical Research (搜索) in New Zealand.